Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
What duration of androgen deprivation therapy do you use for patients with pN+ prostate cancer undergoing upfront adjuvant RT after a radical prostatectomy and pelvic lymph node dissection?
As @Dr. First Last mentioned, the Messing randomized trial (ECOG 3886) showed that lifelong ADT (vs. observation) improved overall survival in patients with pN+ prostate cancer after radical prostatectomy. This trial provides the only level 1 evidence for this patient population. Therefore, ADT shou...
Are there any subgroups of patients with advanced/metastatic NSCLC for whom you are using PD-1 inhibitors in the first-line setting, either alone or in combination with platinum-based chemotherapy?
With the advent of the 024 study pitting single agent Pembrolizumab vs standard chemotherapy in treatment-naive, advanced NSCLC showing a PFS and OS benefit in individuals whose tumors harbor high levels of PDL1 expression (> 50%), one can certainly make a strong case for testing all patients for PD...
Is there a role for atezolizumab as a first-line agent for metastatic urothelial carcinomas?
The first question is whether the patient can tolerate cisplatin-based chemotherapy and whether or not they received (neoadjuvant or adjuvant) cisplatin-based chemotherapy within at least 1 year (if received peri-operative cisplatin-based therapy, it is a longer discussion regarding re-challenge tha...
For lung cancer patients who experience grade 3/4 toxicity from a PD-1 inhibitor necessitating cessation of therapy, but whose tumor has responded to the treatment, do you consider restarting PD-1 inhibitor therapy at the time when they progress again?
This is a highly challenging question that all of us face now with increasing frequency given the ever-widening utilization of checkpoint inhibitors. A decision as to resuming an anti-PD-1/PD-L1 agent in a patient who suffered a serious immune-mediated side effect clearly requires great judgment and...
For the first-line treatment of metastatic lung adenocarcinoma without a targetable driver mutation, do you routinely add bevacizumab to the chemotherapy backbone in the absence of a contraindication to the drug?
That is a really good question. In my practice, I typically will use carboplatin plus pemetrexed for 4-6 cycles followed by maintenance pemetrexed. The addition of bevacizumab consistently improves response rates when added to chemotherapy, so if I have a patient that is symptomatic from local disea...
How do you treat patients with small cell lung cancer that is primarily refractory to platinum/etoposide (i.e. disease that continues to progress despite first-line chemotherapy?)
Unfortunately I have rarely seen second-line therapy provide meaningful benefit in patients with previously treated small cell lung cancer and have little enthusiasm for treating these patients outside of a clinical trial. Recently reported data for therapies such as nivolumab+Ipilimumab and rovalpi...
What adjuvant chemotherapy regimen is most appropriate for a patient with local recurrence several years after surgery and ddAC-T for localized breast cancer?
In this situation, it is preferable to use a chemotherapy regimen that has been shown to be effective in the adjuvant setting. For a patient who has already received ddAC-T, my choice would be TC (docetaxel/cyclophosphamide), or even CMF. The role of chemotherapy for locoregional recurrence is still...
When patients with EGFR-mutant or ALK-translocated advanced NSCLC progress after all available targeted therapies, do you use chemotherapy or PD-1/PD-L1 inhibitor therapy as the next line?
In general I favor chemotherapy or a clinical trial for patients with sensitizing EGFR mutations after they have exhausted available EGFR TKI therapy. The EGFR mutated subgroups in both the nivolumab second line registration trials and the pembrolizumab second line registration trial trended toward ...
How do you approach first line therapy for metastatic, hormone receptor positive, HER2 negative breast cancer in post menopausal women?
I use palbociclib and letrozle in the vast majority of women who come to me with de novo ER positive MBC. If a woman recurs with ER positive MBC while on an AI, I use faslodex and palbociclib. Ribociclib also has shown benefit in the recently completed phase III (MONALESSA2) trial, but it is not yet...
Do you consider use of TIP as first-line therapy for poor-risk advanced germ cell tumors?
Unequivocally no. TIP seems clearly more toxic and achieves results no different than VIP or BEP given at high volume centers. TIP will not ever be compared to either and is going nowhere. In my view and the view of other testis cancer experts, the most important aspect is that these uncommon patien...